NEXT MENTIONED IN PUBLICATION FROM GREATER COPENHAGEN

In a publication from Greater Copenhagen. Under “Life Science” is a short overview over the development in clinical trials in 2016 as well as mentions of NEXT and the value of clinical trials (as recorded by Copenhagen Economics).

Read the publication here

RIGSHOSPITALET FIRST IN THE WORLD TO INTRODUCE NEW IMMUNOTHERAPY FOR CANCER PATIENTS FROM THE NEXT PARTNER ROCHE A/S

Read it here.

NEXT Annual Report 2016

The NEXT annual report 2016 is now available. The highlights are as follows:
NEXT expanded the number of clinical research centres from two to four during 2016 due to a second round of investments from Innovation Fund Denmark, the regions and new pharmaceutical partners.
The number of clinical trials initiated in 2016 was 22, which exceeded the goal of 13 by nine trials. Nevertheless, the number was a drop of six compared to 2015 where 28 clinical trials were initiated. However, as our analysis indicated a general drop in the number of early phase trials in the EU, the result was found satisfactory as NEXT in two years had experienced a total of 50 initiated early phase clinical trials.
In 2016, the NEXT Core Function was strengthened with two Centre Coordinators and one Partnership Manager, which were tasked with facilitating national coordination, improving metrics, overseeing feasibilities and ongoing trials, and administering funding in NEXT.
In 2017, NEXT aims to further emphasize the national collaboration and excellence in clinical trial performance. Furthermore, NEXT will intensify activities to increase visibility within the pharmaceutical industry, for instance by offering associated partnerships and making NEXT visible to the industry. More disease areas will be part of NEXT in 2017 and onwards, and finally, NEXT will develop a long-term business plan for a sustainable NEXT by 2019.

EXECUTIVE SUMMARY OF THE REPORT “THE VALUE OF CLINICAL TRIALS IN DENMARK” AVAILABLE

NEXT, The Danish Association of the Pharmaceutical Industry (Lif) and Invest in Denmark published a report made by Copenhagen Economics in March 2017 in Danish.
The report quantifies the value generated by clinical trials in Denmark, and main conclusions are that clinical trials by pharmaceutical companies deliver value to the Danish society. On average, a clinical trial improves GDP by DKK 0.9m and the public budget by DKK 1.2m.
The positive economic effects arise from trials conducted in Denmark through several drivers: More and better healthcare, highly productive jobs and new research in Life Sciences.
The executive summary is now available in English.

Download (PDF, 452KB)

REPORT BY COPENHAGEN ECONOMICS: THE VALUE OF CLINICAL TRIALS IN DENMARK

NEXT, The Danish Association of the Pharmaceutical Industry (Lif) and Invest in Denmark have published a report made by Copenhagen Economics which quantifies the value generated by clinical trials in Denmark.
The main conclusions of the report are: Clinical trials by pharmaceutical companies deliver value to the Danish society. On average, a clinical trial improves GDP by DKK 0.9m and the public budget by DKK 1.2m.
The positive economic effects arise from trials conducted in Denmark through several drivers: More and better healthcare, highly productive jobs and new research in Life Sciences.

The executive summary is available in English here: engelsk resume

The full report is available in Danish.

Download (PDF, 1.46MB)

EXPANSION OF CENTER FOR ONCOLOGY & HAEMATOLOGY

NEXT Center for Oncology & Haematology is expanding with Department of Haematology at Odense University Hospital headed by professor Niels Abildgaard and Department of Oncology at Vejle Sygehus (Hospital Little Belt) headed by professor Anders Møller Jakobsen. Moreover, Department of Oncology at Odense University Hospital headed by professor Per Pfeiffer is upgrading the collaboration with NEXT.

Professor Niels Abildgaard says:
“We are very happy to become a part of NEXT and hope to attract more commercial phase I-II clinical trials through this collaboration which will contribute to a clearer haematological profile in the center.”

Professor Anders Møller Jakobsen says that it is “important to get Vejle Sygehus on the map and this allows us to offer more treatment options to the patients.”

SANOFI, CELGENE AND BRISTOL-MYERS SQUIBB HAVE BECOME ASSOCIATED PARTNERS

NEXT formally presented Sanofi, Celgene and Bristol-Myers Squibb as associated partners at the MedWatch morning meeting on 7 February 2017: ‘Learn more about next steps in the large public-private venture’. Hereby, NEXT expands with a new type of partnership for companies wishing to participate in the partnership collaboration on clinical research and get access to NEXT’s platform and optimized processes in relation to start-up and conduct of clinical trials.

From left: Anders Thelborg, CEO, Bristol-Myers Squibb; Charlotte Søby Vestergaard, Country Chair, Sanofi; Tina Buhl, Head of Communication & Senior Manager, Celgene; Britta Smedegaard Andersen, NEXT Project director and Thomas Kongstad Petersen, Chairman of NEXT steering committee at the MedWatch morning meeting 7 February, 2017, where the associates were presented.

NEXT hopes that more companies will follow suit this year.

Charlotte Søby Vestergaard, Country Chair, Sanofi Denmark, says about the collaboration:
“Sanofi looks forward to becoming an associated partner of NEXT. Sanofi has a broad and diverse pipeline, which fits well into the NEXT focus areas. Therefore, Sanofi expects good synergy with the NEXT partnership adding the possibility to attract early clinical trials within several disease areas. In close cooperation with NEXT, Sanofi also gets the opportunity to focus on new areas such as diabetes and cardiovascular diseases, areas in which Sanofi has a long history of research and development of new and innovative treatments. Furthermore, one potential positive aspect for Sanofi could be a collaboration within rare diseases where Denmark has unique opportunities to take a leading position at an international level.”

Also for Celgene it has been important to reinforce their interest in joining NEXT as an associated partner:
“Through the partnership with NEXT, we get the opportunity to contribute to further strengthening Denmark’s position within clinical research. At Celgene we believe that with the strong infrastructure provided by NEXT, we can attract more clinical trials to Denmark, especially studies in the important early phase. However, at the end of the day, hopefully it will be the individual patient, who will gain when Denmark is strengthened as a research nation,” says Bengt Gustavsson, Medical Director, Celgene.

And Bristol-Myers Squibb says:
“Bristol-Myers Squibb conduct numerous clinical trials in Denmark, and for us it has been an obvious decision to join the NEXT collaboration. We hope that it will contribute to attracting more clinical trials to Denmark, both for the benefit of patients with a serious illness such as cancer, and for the many doctors and nurses (and other health professionals) who will carry out these trials, “says Anders Thelborg, CEO of Bristol-Myers Squibb Denmark.

BUSINESS MEETING AT CENTER FOR ONCOLOGY & HAEMATOLOGY ON 29 MAY

NEXT Center for Oncology & Haematology will hold a business meeting on 29 May from 11-15 in Odense. At the meeting, there will be an introduction to the center and presentations from various departments of the center as well as company presentations. All companies interested in performing clinical phase I-II trials in Denmark within oncology and haematology will be invited. Interested parties are welcome to contact NEXT Partnership Manager, Ask Aabenhus (aaa@nextpartnership.dk).

NEW YEAR’S RECEPTION IN CENTER FOR DERMATOLOGY

On 12 January, NEXT Center for Dermatology celebrated the new year with a reception at Bispebjerg Hospital. At the event, Center for Dermatology was introduced and the center’s special research skills were communicated. Furthermore, several speeches were given by NEXT and by NEXT partners LEO Pharma and Novartis. The companies shared the benefits of the NEXT partnership and their future expectations for this collaboration. Numerous pharma and medico companies, representatives from the regions, Invest in Denmark as well as personnel from various NEXT Centers attended the meeting.
Lise Warming, Country Medical Head, Novartis, says about the collaboration: “The collaboration with NEXT gives Novartis new opportunities to attract additional clinical research to Denmark. NEXT offers a structure providing the potential for an effective and constructive collaboration with skilled and dedicated researchers and clinicians in order to develop new medicine. Already today, Novartis can see an effect both on increased research activities and on important global competition parametres such as speed and flexibility. It is our impression that NEXT has given clinicians increased opportunities to engage in relevant research projects”.